<DOC>
	<DOCNO>NCT01077349</DOCNO>
	<brief_summary>This study seek determine early continuous High Volume Veno-venous Hemofiltration ( HVHF ) reduce 30-day cause mortality post-cardiac surgery patient develop shock require high dos catecholamine .</brief_summary>
	<brief_title>High Volume Veno-venous Hemofiltration Versus Standard Care Post-cardiac Surgery Shock</brief_title>
	<detailed_description>Study Title - Early continuous high volume veno-venous hemofiltration vs. standard care post-cardiac surgery shock require high dose catecholamine . An open label randomize multicenter control trial . The HEROICS Study : HEmofiltration Rescue severe shOck followIng Cardiac Surgery . Clinical Phase - III Study Rationale - Systemic inflammatory response syndrome associate cardiac surgery cardiopulmonary bypass ( CPB ) share many pathophysiologic feature septic shock post-resuscitation syndrome . Since high volume hemofiltration show markedly improve hemodynamic profile survival situation , strong rationale testing , adequately power randomize control trial , purification technique patient develop post-cardiac surgery shock require high dos catecholamine . Trial Design - The propose study compare high volume hemofiltration ( 80 ml/kg/h maximum 8L/h ) 48 hour follow heart surgery standard treatment , extra-renal replacement therapy ( CVVHDF mode , total effluent &lt; 35 ml/kg/h ) initiate follow criterion meet : - Serum creatinine &gt; 350 micromol/L increase x3.0 pre-operative value OR - Diuresis &lt; 0.3 ml/kg/h 24 hour despite adequate fluid resuscitation OR - Or serum urea &gt; 36 mmol/l OR - Or life threaten hyperkalemia . In experimental arm , hemofiltration stop 48h diuresis &gt; 1500 ml without diuretic IV infusion catecholamine less 0.1 microg/kg/min epinephrine , 0.2 microg/kg/min norepinephrine sum epinephrine + norepinephrine/2 less 0.1 microg/kg/min . In case , hemodiafiltration ( CVVHDF ) initiate objective reach , equal flow rate dialysate reinfusion fluid , sum 35 ml/kg/h ( maximum 3500 ml/h ) . Subject Participation - 90 day Rationale Number Subjects - The study follow sequential analytical plan stop rule base triangular test . The expected mortality control group expect 25 % expect absolute mortality reduction experimental treatment 12 % . For 80 % power 5 % Î±-risk , study characteristic , calculate triangular test , follow : maximum 540 subject include 90 % probability stop study 330 subject include . With inclusion rate 120-150 patient per year , maximum duration study 2 year 3 month probability stop study 18 month 90 % . Approximate duration Study - 27 month Study Objective ( ) Primary - The primary study outcome death cause 30 day randomisation . Secondary 1 . Mortality 60 90 day follow study enrollment 2 . ICU Hospital mortality 3 . Mortality adjust type surgery patient severity randomization 4 . Duration catecholamine infusion number catecholamine-free day 30 day follow study enrollment 5 . Duration renal replacement therapy number renal replacement therapy -free day 30 day follow study enrollment 6 . Recovery renal failure dialysis independent survival 7 . Duration mechanical ventilation number mechanical ventilation -free day 30 day follow study enrollment 8 . SOFA score day 1 , 2 ,3 ,4 ,7 ,15 , 30 follow study enrollment 9 . Reduction marker overt coagulation inflammation day 2 , 4 7 follow study enrollment 10 . ICU Hospital length stay 11 . Mortality analysis accord subgroup patient ( type surgery , severity randomization , renal function randomization ) Approximate Number Subjects - 330 Approximate Number Study Centres - 8 centre distribute France participate study . Treatment Administration - Each participant randomise receive high volume hemofiltration ( CVVH , 80 ml/kg/h maximum 8L/h ) 48 hour follow heart surgery standard treatment , extra-renal replacement therapy ( CVVHDF mode , total effluent &lt; 35 ml/kg/h ) initiate criterion renal failure meet . Safety Evaluation - Safety individual patient assess ongoing basis physical examination , include vital sign , outputs dialysis machine record , laboratory assessment , monitor adverse event . Overall study safety ensure Independent Data Safety Monitoring Committee , independent Trial investigator , perform ongoing review predefined safety parameter study conduct . Efficacy Evaluation - Overall survival 30 day post randomisation Statistical Analysis - The first analysis schedule inclusion 60 subject . Thereafter , stop rule schedule sequentially apply , base triangular test . This allow u stop trial soon sufficient evidence one 2 treatment strategy dangerous long chance demonstrate postulate treatment difference 12 % , control risk type I II error . Sequential analysis conduct every 20 patient . The baseline outcome variable compare use Students test , Chi square Mann-Whitney U test appropriate . Kaplan-Meier survival curve 30 day follow randomization compare log-rank test. , survival calculate date randomization .</detailed_description>
	<mesh_term>Shock</mesh_term>
	<criteria>1 . Cardiac surgery cardiopulmonary bypass 2 . Patient still high dos catecholamines 3 24 hour follow cardiacsurgical ICU admission . High dos catecholamine define IV infusion : 1 . Epinephrine &gt; 0.2 microg/kg/min 2 . Norepinephrine &gt; 0.4 microg/kg/min 3 . Epinephrine + ( Norepinephrine /2 ) &gt; 0.2 microg/kg/min 4 . Cardiac assistance use ECMO/ECLS technique consider equivalent high dos catecholamine . 3 . Informed consent obtain next kin consent obtain , intervention randomize , write informed consent obtain patient soon regain consciousness . This practice consistent French law clinical research . 1 . Age &lt; 18 year 2 . Pregnancy 3 . Chronic hemodialysis prior heart surgery 4 . Body weight &gt; 120 kg 5 . Moribund state , define SAPS 2 score &gt; 90 6 . Severe underlying disease survival expectancy le 8 day 7 . Decision withhold withdraw active therapeutic 8 . PrismaFlex machine unavailable unit 9 . Intravascular access dialysis catheter impossible</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>90 Years</maximum_age>
	<verification_date>October 2012</verification_date>
	<keyword>Cardiac surgery</keyword>
	<keyword>Shock</keyword>
	<keyword>Continuous Veno-Venous Haemofiltration</keyword>
	<keyword>Continuous Renal Replacement Therapy</keyword>
	<keyword>Renal Insufficiency</keyword>
	<keyword>Acute</keyword>
</DOC>